Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Expert Ratings for Applied Materials

Analysts have provided the following ratings for Applied Materials (NASDAQ:AMAT) within the last quarter:

Trump SPAC Deal Finally Files A Proxy: 10 Key Details We Now Know

Trump SPAC Deal Finally Files A Proxy: 10 Key Details We Now Know

Seven months after announcing a SPAC merger, a social media company owned by former President Donald Trump has filed its proxy. Here are the key details from the more than 250 pages contained in the proxy filing.

What 6 Analyst Ratings Have To Say About Bandwidth

What 6 Analyst Ratings Have To Say About Bandwidth

Analysts have provided the following ratings for Bandwidth (NASDAQ:BAND) within the last quarter:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Credit Suisse Maintains Outperform Rating for Cisco Systems: Here's What You Need To Know

Credit Suisse has decided to maintain its Outperform rating of Cisco Systems (NASDAQ:CSCO) and lower its price target from $73.00 to $72.00. Shares of Cisco Systems are trading down 0.14% over the last 24 hours, at $49.49 per share.

DA Davidson Maintains Buy Rating for AEye: Here's What You Need To Know

DA Davidson has decided to maintain its Buy rating of AEye (NASDAQ:LIDR) and lower its price target from $15.00 to $12.00. Shares of AEye are trading up 9.45% over the last 24 hours, at $5.38 per share. A move to $12.00 would account for a 122.84% increase from the current…

HC Wainwright & Co. Maintains Buy Rating for Motus GI Hldgs: Here's What You Need To Know

HC Wainwright & Co. has decided to maintain its Buy rating of Motus GI Hldgs (NASDAQ:MOTS) and lower its price target from $2.00 to $1.50. Shares of Motus GI Hldgs are trading up 2.97% over the last 24 hours, at $0.27 per share.

Veru Whale Trades For May 16

A whale with a lot of money to spend has taken a noticeably bearish stance on Veru. Looking at options history for Veru (NASDAQ:VERU) we detected 14 strange trades.

inkl

Read news from The Economist, FT, and more,
with one subscription

Compass Point Maintains Neutral Rating for AFC Gamma: Here's What You Need To Know

Compass Point Maintains Neutral Rating for AFC Gamma: Here's What You Need To Know

Compass Point has decided to maintain its Neutral rating of AFC Gamma (NASDAQ:AFCG) and lower its price target from $20.00 to $17.50. Shares of AFC Gamma are trading down 4.66% over the last 24 hours, at $17.00 per share. A move to $17.50 would account for a 2.94% increase from…

Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know

Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know

Piper Sandler has decided to maintain its Neutral rating of Pacific Biosciences (NASDAQ:PACB) and lower its price target from $13.00 to $6.00. Shares of Pacific Biosciences are trading down 2.74% over the last 24 hours, at $5.68 per share.

Cowen & Co. Maintains Outperform Rating for DarioHealth: Here's What You Need To Know

Cowen & Co. Maintains Outperform Rating for DarioHealth: Here's What You Need To Know

Cowen & Co. has decided to maintain its Outperform rating of DarioHealth (NASDAQ:DRIO) and raise its price target from $14.00 to $18.00. Shares of DarioHealth are trading up 5.8% over the last 24 hours, at $6.20 per share.

Here's Why Surgalign Holdings Shares Are Falling Today

Here's Why Surgalign Holdings Shares Are Falling Today

Surgalign Holdings Inc (NASDAQ: SRGA) shares are trading lower by 19.73% at $0.15 after the company announced a 1-for-30 reverse stock split. The 1-for-30 reverse stock split will take effect at the opening of trading on the Nasdaq Global Select Market on Tuesday.

C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers

C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers

C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors.

Orbital Energy Stock Gains After Q1 Results; Reiterates FY22 Forecast

Orbital Energy Stock Gains After Q1 Results; Reiterates FY22 Forecast

Orbital Energy Group Inc (NASDAQ:OEG) reported first-quarter revenue of $70.25 million, compared to $5.56 million in 1Q21, marginally missing the consensus of $70.49 million. EPS loss widened to $(0.44) from $(0.36) in 1Q21, missing the consensus of $(0.05). OEG reported a gross profit of $11.58 million, compared to a loss of $(2.52)…

What's Going On With Sundial Growers Stock?

What's Going On With Sundial Growers Stock?

Sundial Growers Inc (NASDAQ: SNDL) shares are trading significantly higher Monday ahead of the company's first-quarter financial results, which are set to be released after the bell.

Get all your
news in one place.

100's of premium titles.
One news app.

Check Out What Whales Are Doing With Meta Platforms

A whale with a lot of money to spend has taken a noticeably bullish stance on Meta Platforms. Looking at options history for Meta Platforms (NASDAQ:FB) we detected 32 strange trades.

The Final Call: Time To Buy These Undervalued Stocks

On CNBC's "The Final Call," Carter Worth named Intuit Inc. (NASDAQ: INTU). Shares of the company have lost more than 40% year to date.

Ryanair FY22 Loss Narrows, Expects To Return To Profitability In FY23

Ryanair Holdings plc (NASDAQ:RYAAY) reported FY22 revenue growth of 193% year-over-year to €4.8 billion. The company reported an FY22 net loss of €(355) million, compared to a €(1.05) billion loss a year ago. Scheduled revenues were up 156% Y/Y, reflecting a rise in traffic from 27.5 million customers to 97.1 million. Ancillary…

5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

Get all your
news in one place.

100's of premium titles.
One news app.

Wedbush Upgrades Netflix As 'Immensely Profitable, Slow-Growth Company': What Else Interests The Analyst?

Netflix Inc (NASDAQ: NFLX) shares traded higher by 3.3% on Monday after the company received an upgrade on Wall Street. The Analyst: Wedbush analyst Michael Pachter upgraded Netflix from Neutral to Outperform and reiterated his $280 price target.

Earnings Preview For Kamada

Kamada (NASDAQ:KMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Kamada will report an earnings per share (EPS) of $0.02.

Expert Ratings for Akebia Therapeutics

Over the past 3 months, 4 analysts have published their opinion on Akebia Therapeutics (NASDAQ:AKBA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

CrowdStrike Holdings Whale Trades For May 16

A whale with a lot of money to spend has taken a noticeably bullish stance on CrowdStrike Holdings. Looking at options history for CrowdStrike Holdings (NASDAQ:CRWD) we detected 14 strange trades.

Preview: MediWound's Earnings

MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that MediWound will report an earnings per share (EPS) of $-0.11.

Earnings Preview: ObsEva

ObsEva (NASDAQ:OBSV) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that ObsEva will report an earnings per share (EPS) of $-0.20.

Expert Ratings for Sterling Check

Over the past 3 months, 7 analysts have published their opinion on Sterling Check (NASDAQ:STER) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

1 … 529 530 531 532

People

199,674 stories

Michael Pachter

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Applied Materials

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

392,798 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play